Alternatives to death: Understanding androgen-independent prostate cancer

被引：0
|
作者：
Joel B. Nelson
机构：
[1] Brady Urological Institute Johns Hopkins Medical Institutions ,
来源：
Nature Medicine | 1998年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Decreased levels of caveolin promote sensitivity to androgen withdrawal in prostate cancer cells, suggesting another therapeutic target for the treatment of prostate cancer (pages 1062–1064).
引用
收藏
页码：1011 / 1012
页数：1
相关论文
共 50 条
  • [1] Alternatives to death: Understanding androgen-independent prostate cancer
    Nelson, JB
    [J]. NATURE MEDICINE, 1998, 4 (09) : 1011 - 1012
  • [2] The development of androgen-independent prostate cancer
    Brian J. Feldman
    David Feldman
    [J]. Nature Reviews Cancer, 2001, 1 : 34 - 45
  • [3] The Progression to Androgen-Independent Prostate Cancer
    Matusik, Robert J.
    [J]. JOURNAL OF ANDROLOGY, 2010, : 23 - 23
  • [4] Chemotherapy for androgen-independent prostate cancer
    Petrylak, DP
    [J]. WORLD JOURNAL OF UROLOGY, 2005, 23 (01) : 10 - 13
  • [5] Chemotherapy for androgen-independent prostate cancer
    Daniel P. Petrylak
    [J]. World Journal of Urology, 2005, 23 : 10 - 13
  • [6] The development of androgen-independent prostate cancer
    Feldman, BJ
    Feldman, D
    [J]. NATURE REVIEWS CANCER, 2001, 1 (01) : 34 - 45
  • [7] Targeted therapy in androgen-independent prostate cancer
    Sternberg, C. N.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 21 - 22
  • [8] The use of thalidomide in androgen-independent prostate cancer
    Cox, Michael C.
    Dahut, William L.
    Figg, William D.
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 246 - 249
  • [9] Androgen-independent prostate cancer: a growth area?
    Wyllie, MG
    [J]. BJU INTERNATIONAL, 2003, 92 (09) : 1037 - 1038
  • [10] Docetaxel in androgen-independent prostate cancer: An update
    Khan, MA
    Carducci, MA
    Partin, AW
    [J]. BJU INTERNATIONAL, 2004, 94 (09) : 1209 - 1210
12345